Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Venture Capital Funding Issue Splits House, Senate On SBIR Reauthorization

This article was originally published in The Gray Sheet

Executive Summary

While Small Business Innovation Research reauthorization bills are making headway through the House and Senate, the two bodies differ on how much SBIR funding can go to start-up firms that are majority-owned by venture capitalists and other private investors.

You may also be interested in...

Updated SBIR Grants May Already Need A Fix To Keep Up With The Times

Just as the Small Business Innovation Research program achieved a congressional fix for the knotty problem of letting companies with VC support apply for the “valley of death” grants, it may have fallen behind again with its de facto exclusion of virtual start-ups. Companies have until July 16 to comment on the program’s updated implementing regulation.

Reform Of Federal Small Business Research Funding Program Delayed Again

Congress has again put off longer term reauthorization and reform of the Small Business Innovation Research Program, as the House and Senate remain at odds over the appropriateness of funding majority venture-capital-backed companies

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add a new product – Tibsovo, Servier’s treatment for IDH1-mutated acute myeloid leukemia and IDH1-mutated cholangiocarcinoma.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts